The DOI matches its Crossref record; 210 of the 210 references it cites were found in a registry or an index.
Oesophageal cancer
Open accessAbstract
Oesophageal cancer is the sixth most common cause of cancer-related death worldwide and is therefore a major global health challenge. The two major subtypes of oesophageal cancer are oesophageal squamous cell carcinoma (OSCC) and oesophageal adenocarcinoma (OAC), which are epidemiologically and biologically distinct. OSCC accounts for 90% of all cases of oesophageal cancer globally and is highly prevalent in the East, East Africa and South America. OAC is more common in developed countries than in developing countries. Preneoplastic lesions are identifiable for both OSCC and OAC; these are frequently amenable to endoscopic ablative therapies. Most patients with oesophageal cancer require extensive treatment, including chemotherapy, chemoradiotherapy and/or surgical resection. Patients with advanced or metastatic oesophageal cancer are treated with palliative chemotherapy; those who are human epidermal growth factor receptor 2 (HER2)-positive may also benefit from trastuzumab treatment. Immuno-oncology therapies have also shown promising early results in OSCC and OAC. In this Primer, we review state-of-the-art knowledge on the biology and treatment of oesophageal cancer, including screening, endoscopic ablative therapies and emerging molecular targets, and we discuss best practices in chemotherapy, chemoradiotherapy, surgery and the maintenance of patient quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–210 of 210
Proposed follow up programme after curative resection for lower third oesophageal cancer
Moyes, L., Anderson, J., & Forshaw, M. (2010) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-8-75 · Cited by 27
Biomarkers in Barrett’s Esophagus
Bansal, A. K., & Fitzgerald, R. C. (2015) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2015.02.008 · Cited by 24
Self-citationBrusselaers, N., Mattsson, F., Lindblad, M., & Lagergren, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121928 · Cited by 24
Self-citationDai, J. Y., Tapsoba, J. D. D., Buas, M. F., Onstad, L., Levine, D., Risch, H. A., Chow, W., Bernstein, L., Ye, W., Lagergren, J., et al. (2015) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0507 · Cited by 24
Self-citationCo-morbidity after oesophageal cancer surgery and recovery of health-related quality of life
Backemar, L., Wikman, A., Djärv, T., Johar, A. M., & Lagergren, P. (2016) · British journal of surgery · doi:10.1002/bjs.10248 · Cited by 21
Self-citationZheng, Y., Cao, X., Wen, J., Yang, H., Luo, K., Liu, Q., Huang, Q., Chen, J., & Fu, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123246 · Cited by 20
Rutegård, M., & Lagergren, P. (2008) · Annals of Surgical Oncology · doi:10.1245/s10434-008-9964-4 · Cited by 19
Self-citationHong, L., Zhang, H., Zhao, Q., Han, Y., Yang, J., & Brain, L. (2013) · Diseases of the Esophagus · doi:10.1111/dote.12016 · Cited by 16
Schandl, A. R., Johar, A. M., Lagergren, J., & Lagergren, P. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012624 · Cited by 16
Self-citationvan der Schaaf, M., Rutegård, M., & Lagergren, P. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2690-y · Cited by 13
Self-citation
Cited by
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
Kelly, R. J., Ajani, J. A., Kuzdzal, J., Zander, T., Van Cutsem, E., Piessen, G., Mendez, G., Feliciano, J., Motoyama, S., Lièvre, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032125 · Cited by 1,827
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
Doki, Y., Ajani, J. A., Kato, K., Xu, J., Wyrwicz, L., Motoyama, S., Ogata, T., Kawakami, H., Hsu, C.-H., Adenis, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2111380 · Cited by 1,230
Epidemiology of esophageal cancer: update in global trends, etiology and risk factors
Uhlenhopp, D. J., Then, E. O., Sunkara, T., & Gaduputi, V. (2020) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-020-01237-x · Cited by 766
Advances in targeted therapy for esophageal cancer
Yang, Y.-M., Hong, P., Xu, W. W., He, Q.-Y., & Li, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00323-3 · Cited by 508
Shah, M. A., Kojima, T., Hochhauser, D., Enzinger, P., Raimbourg, J., Hollebecque, A., Lordick, F., Kim, S.-B., Tajika, M., Kim, H. T., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5441 · Cited by 496
Self-citation
Metadata
- Authors
- Smyth, E. C., Lagergren, J., Fitzgerald, R. C., Lordick, F., Shah, M. A., Lagergren, P., & Cunningham, D.
- Venue
- Nature Reviews Disease Primers
- Published
- 2017-07-27
- Volume
- 3
- Issue
- 1
- Pages
- 17048-17048
- ISSN
- 2056-676X (ISSN-L)
- OpenAlex
- W4210685329
- Cited by
- 1,012
- References
- 210
- FWCI
- 12.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.